BACKGROUND: Thrombocytopenia is a major side effect of linezolid therapy. However, there are few reports about the risk factors for linezolid-induced thrombocytopenia. OBJECTIVE: The aim of this study is to evaluate the risk factors for thrombocytopenia in patients who undergo linezolid therapy. SETTING: Aomori Prefectural Central Hospital in Japan, a tertiary 695 beds hospital. METHOD: A retrospective review was performed using the hospital's medical records. From January 2010 to August 2012, 75 adult patients who received linezolid therapy were enrolled in this study. MAIN OUTCOME MEASURE: Linezolid-induced thrombocytopenia was defined as a decrease in the patient's platelet count to <10 × 10⁴/μL or a reduction of ≥30 % from their baseline value. Odds ratios (OR) for thrombocytopenia were analyzed using multivariate stepwise logistic regression analysis. RESULTS: Thrombocytopenia occurred in 29 patients (38.6 %), seven of whom required platelet transfusions. The patients who developed thrombocytopenia were significantly older, displayed a significantly higher frequency of renal insufficiency, and received linezolid therapy for significantly longer than the patients without thrombocytopenia. Stepwise logistic regression analysis suggested that receiving linezolid therapy for ≥14 days was a significant risk factor for thrombocytopenia [OR 13.3, 95 % confidence interval (CI) 3.2-55.6, p < 0.01], whereas the creatinine clearance rate exhibited a significant negative correlation with the incidence of the condition [OR 0.98, 95 % CI 0.96-0.99, p = 0.037]. The incidence of thrombocytopenia among the patients who demonstrated creatinine clearance rates of <30 mL/min was 60 % (12/20), which was significantly higher than that observed among the patients who displayed creatinine clearance rates of more than 60 mL/min (26.4 %, 9/34, p = 0.014). CONCLUSION: Receiving linezolid therapy for ≥14 days and a low creatinine clearance rate were suggested to be risk factors for linezolid-induced thrombocytopenia. The platelet counts of patients with these risk factors should be closely monitored.
BACKGROUND:Thrombocytopenia is a major side effect of linezolid therapy. However, there are few reports about the risk factors for linezolid-induced thrombocytopenia. OBJECTIVE: The aim of this study is to evaluate the risk factors for thrombocytopenia in patients who undergo linezolid therapy. SETTING: Aomori Prefectural Central Hospital in Japan, a tertiary 695 beds hospital. METHOD: A retrospective review was performed using the hospital's medical records. From January 2010 to August 2012, 75 adult patients who received linezolid therapy were enrolled in this study. MAIN OUTCOME MEASURE: Linezolid-induced thrombocytopenia was defined as a decrease in the patient's platelet count to <10 × 10⁴/μL or a reduction of ≥30 % from their baseline value. Odds ratios (OR) for thrombocytopenia were analyzed using multivariate stepwise logistic regression analysis. RESULTS:Thrombocytopenia occurred in 29 patients (38.6 %), seven of whom required platelet transfusions. The patients who developed thrombocytopenia were significantly older, displayed a significantly higher frequency of renal insufficiency, and received linezolid therapy for significantly longer than the patients without thrombocytopenia. Stepwise logistic regression analysis suggested that receiving linezolid therapy for ≥14 days was a significant risk factor for thrombocytopenia [OR 13.3, 95 % confidence interval (CI) 3.2-55.6, p < 0.01], whereas the creatinine clearance rate exhibited a significant negative correlation with the incidence of the condition [OR 0.98, 95 % CI 0.96-0.99, p = 0.037]. The incidence of thrombocytopenia among the patients who demonstrated creatinine clearance rates of <30 mL/min was 60 % (12/20), which was significantly higher than that observed among the patients who displayed creatinine clearance rates of more than 60 mL/min (26.4 %, 9/34, p = 0.014). CONCLUSION: Receiving linezolid therapy for ≥14 days and a low creatinine clearance rate were suggested to be risk factors for linezolid-induced thrombocytopenia. The platelet counts of patients with these risk factors should be closely monitored.
Authors: An S De Vriese; Rudy Van Coster; Joel Smet; Sara Seneca; Andrew Lovering; Lindsey L Van Haute; Ludo J Vanopdenbosch; Jean-Jacques Martin; Chantal Ceuterick-de Groote; Stefaan Vandecasteele; Johan R Boelaert Journal: Clin Infect Dis Date: 2006-03-13 Impact factor: 9.079
Authors: J G Slatter; D J Stalker; K L Feenstra; I R Welshman; J B Bruss; J P Sams; M G Johnson; P E Sanders; M J Hauer; P E Fagerness; R P Stryd; G W Peng; E M Shobe Journal: Drug Metab Dispos Date: 2001-08 Impact factor: 3.922
Authors: Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth Journal: Antimicrob Agents Chemother Date: 2003-09 Impact factor: 5.191
Authors: Wendy B Bernstein; Richard F Trotta; James T Rector; Jeffery A Tjaden; Anthony J Barile Journal: Ann Pharmacother Date: 2003-04 Impact factor: 3.154